From controlling body temperature and flushing out toxins, adequate hydration plays a vital role in our general health and well-being, water is a life essential. However, while dehydration garners significant attention, overhydration, or drinking excessive amounts of water, is a condition that can have serious and sometimes fatal consequences.

Although it may sound bizarre since drinking water is said to be the solution for most health related problems it is important to recognize how much water is considered "too much" or the risks involved with being overhydrated can maintain a healthy balance.

What Is Water Intoxication?

Water intoxication, also termed hyperhydration, water poisoning or water toxemia, develops when an individual drinks much more water than the kidney can excrete. The main function of the kidneys in the human body is the processing and excretion of excess water. However, the human kidneys can process only up to 0.8 to 1.0 liters of water at a time. Drinking an amount that exceeds this may overwhelm the kidneys and put the electrolyte balance out of sync in the human body.

Electrolytes, especially sodium, are essential in maintaining fluid balance within and outside cells. Hyponatremia is the condition when sodium levels fall below 135 mmol/L, resulting from excessive water intake. This causes water to shift into cells, swelling them. In the brain, this can cause severe complications, including coma or even death.

Symptoms of Water Intoxication

The symptoms of water intoxication vary from mild to severe. Early symptoms are often similar to dehydration, which makes self-diagnosis challenging. Common symptoms include:

• Headaches
• Nausea and vomiting
• Muscle cramps or weakness
• Fatigue or drowsiness
• Confusion and disorientation

In more serious cases, water intoxication can cause seizures, loss of consciousness, or swelling in the brain. These complications can be fatal if left untreated.

A notable case occurred in 2007 when a woman participating in a water-drinking contest tragically died after consuming nearly two gallons of water in under two hours. More recently, actress Brooke Shields experienced a grand mal seizure attributed to excessive water consumption.

Causes of Water Intoxication

Water intoxication is rare, but certain scenarios can increase the risk:

1. Sporting Events and Endurance Training

These endurance athletes are prone to water intoxication, especially if they drink large amounts of water without replacing lost electrolytes. Hyponatremia usually happens during long races or marathons as individuals mistake fatigue and muscle cramps for dehydration and continue drinking water in excess.

2. Military Training

Overhydration among military personnel is usually due to severe physical activity in extreme environmental conditions. The total number of hyponatremia cases documented from 2007 through 2022 for the active duty in the United States exceeds 1,600, with a note to this problem on exertion-related overhydration.

3. Mental Health Conditions

Compulsive water drinking, known as psychogenic polydipsia, is linked with some mental illnesses such as schizophrenia and psychosis. People with these conditions tend to drink too much water, causing a hazardous electrolyte imbalance.

4. Drug Abuse

Drugs such as MDMA (ecstasy) raise the body temperature and make people thirsty, and at times, some people tend to drink excess water at events like music festivals. MDMA also leads to urine retention, thus exacerbating the dangers of water intoxication.

How Much Water Is Too Much?

The exact amount of water that causes intoxication varies from one person to another. However, drinking more than 1 liter of water per hour for several hours raises the risk. For healthy individuals, the risk of overhydration is low unless taking part in extreme physical activity or ignoring thirst cues.

Certain medical conditions, such as kidney or liver disorders, can impair the body's ability to process fluids, and even moderate water intake may be harmful. Similarly, certain medications, such as diuretics and antipsychotics, can affect the perception of thirst or fluid regulation.

How Much Water Is Enough?

The widely touted recommendation of eight 8-ounce glasses of water per day has little basis in fact. According to the National Academy of Medicine, a daily total fluid intake is about 15 cups (3.7 liters) for males and 11 cups (2.7 liters) for females, from beverage sources and from food. Usually, about 20 percent of daily hydration comes from foods such as fruits and vegetables.

A better rule of thumb is to listen to your body and drink water based on thirst. Use the color of your urine as an indicator:

• Light yellow urine indicates proper hydration.
• Dark yellow urine may indicate dehydration.

Older adults, whose thirst mechanisms may decline with age, should be proactive about maintaining hydration, especially during illness or hot weather.

Water Intoxication vs. Dehydration

The symptoms of water intoxication—such as headaches, fatigue, and muscle weakness—are similar to those of dehydration. If you are unsure which condition you are experiencing, seek medical attention immediately rather than self-treating with more water.

Preventing Water Intoxication

To avoid the dangers of overhydration:

• Drink water gradually throughout the day rather than consuming large amounts at once.
• Replace lost electrolytes post high-intensity exercise or heavy sweating.
• Consider using sports drinks or salty snacks to help replenish sodium.
• Keep track of fluid consumption during long-duration activities, and do not consume more water than the body is losing in terms of electrolytes.
• If on medications or have specific medical conditions, check with your doctor regarding the safety of drinking water.

For signs of severe water intoxication-including confusion, drowsiness, seizures, and loss of consciousness-customer is advised to seek medical assistance immediately. In the meanwhile, a salty snack would help to temporarily correct low sodium levels.

Hydration is important to health, but overhydration can be a serious risk; the secret is in finding a balance. Drink enough water to satisfy your body, but not so much that it overwhelms your system. Remember, water is life, but moderation keeps it that way.

Hyponatremia (low sodium level in the blood). National Kidney Foundation. 2023.

Water Toxicity. NIH. 2023

Exercise-Associated Hyponatremia: 2017 Update. Front Med (Lausanne). 2017

Update: Exertional Hyponatremia Among Active Component Members of the U.S. Armed Forces, 2007–2022

While GLP-1 weight-loss drugs such as Wegovy and Mounjaro have helped patients lose weight, a major concern has been weight regain once the therapy is stopped. Now, a new study by US scientists suggests that a daily pill may help prevent that rebound weight gain.

According to a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian, switching to the once-daily orforglipron pill may not only help maintain weight loss but also preserve cardiometabolic benefits.

Orforglipron is US drugmaker Eli Lilly’s first oral pill for weight loss, marketed as Foundayo. In April, it received approval from the US Food and Drug Administration (FDA).

Weight Loss With Daily Pill Orforglipron

In the Eli Lilly-funded trial, published in the journal Nature Medicine, researchers found that patients in the Phase 3b clinical trial maintained around 75–80 per cent of their weight loss. They also experienced several additional health benefits, including:

• Reduced waist circumference
• Improved blood pressure
• Better blood sugar control
• Lower triglyceride levels
• Improved cholesterol levels

The Clinical Trial

The ATTAIN-MAINTAIN trial enrolled patients who had already achieved substantial weight loss that later plateaued while taking weekly injectable GLP-1 drugs during the SURMOUNT-5 trial.

The study randomized:

• 205 patients taking tirzepatide
• 171 patients taking semaglutide

The results showed that patients switching from tirzepatide to orforglipron maintained an average of 74.7 per cent of their body weight reduction, compared with 49.2 per cent in the placebo group.

Meanwhile, patients who switched from semaglutide to orforglipron maintained 79.3 per cent of their body weight reduction, compared with 37.6 per cent in the placebo arm.

Over the 52-week trial period, participants treated with orforglipron gained:

• An average of 5 kg (11 lbs) in the tirzepatide group
• An average of 1 kg (2.2 lbs) in the semaglutide group

How The Daily Pill Orforglipron Works

Eli Lilly licensed orforglipron, the active ingredient in Foundayo, from a Japanese pharmaceutical company in 2018.

Like injectable GLP-1 drugs, Orforglipron is available in six doses ranging from 0.8 mg to 17.2 mg. Patients typically begin at the lowest dose and gradually increase under medical supervision.

Also read: Donald Trump Will Have Fourth Medical Checkup In May, Says White House

Unlike some oral GLP-1 drugs, people taking orforglipron do not need to restrict food or drink intake after taking the pill. Researchers say the small molecule is absorbed quickly into the bloodstream and reaches target tissues efficiently.

Orforglipron: Side Effects And Safety Concerns

Foundayo is not approved for use in children and carries warnings about potential thyroid tumours, including thyroid cancer.

The drugmaker advises patients to watch for symptoms such as:

• Lump or swelling in the neck
• Hoarseness
• Trouble swallowing
• Shortness of breath

• Nausea
• Constipation
• Diarrhoea
• Vomiting
• Indigestion
• Stomach pain
• Headache
• Swollen belly
• Fatigue
• Belching
• Heartburn
• Gas
• Hair loss.

In a major development for cancer care in India, Swiss pharmaceutical major Roche Pharma has launched Tecentriq SC, the country’s first subcutaneous (under-the-skin) immunotherapy for lung cancer that can be administered in approximately seven minutes.

While conventional intravenous (IV) infusions can take hours, Tecentriq SC can significantly improve the cancer treatment experience by reducing treatment time by nearly 80 per cent.

The seven-minute injectable immunotherapy has the potential to:

• Treat up to five patients in the time taken to treat one patient through intravenous infusion
• Help optimise healthcare resources
• Lower indirect treatment costs
• Minimise the need for patients to travel long distances
• Reduce the amount of time caregivers spend in hospitals

“With Tecentriq SC, we are bringing an innovation that meaningfully reduces treatment time while maintaining the established efficacy and safety profile of Tecentriq. We believe such advances can play an important role in enabling more patient-centric and future-ready cancer care delivery in India,” said Roche Pharma India Chief Medical Officer Dr Sivabalan Sivanesan, in a statement.

What Is Tecentriq SC? What's The Cost In India?

Tecentriq SC is the first and only PD-(L)1 inhibitor globally with both intravenous (IV) and subcutaneous (SC) formulations across multiple cancers.

First approved by the UK MHRA in 2023 and subsequently by the USFDA in 2024, Tecentriq SC is now approved in more than 85 countries, with over 10,000 patients benefitting globally.

In India, Tecentriq SC is currently approved by the DCGI for adjuvant and metastatic non-small cell lung cancer (NSCLC). NSCLC is the most common form, making up about 80–85% of all cases.

According to Sivanesan, the drug is priced at about "Rs 3.7 lakh per vial".

Also read: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi

How Does Tecentriq SC Work?

Tecentriq SC combines Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology.

The technology uses recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that temporarily increases permeability in the subcutaneous space, enabling rapid dispersion and absorption of the medicine into the bloodstream, the company said.

How Tecentriq SC will Boost Cancer Care In India

The launch of Tecentriq SC also aligns with the broader shift toward decentralised cancer care in India. Shorter administration formats can free up hospital beds, healthcare staff time, and oncology resources at tertiary care centres, while helping shift care delivery to daycare centres and beyond traditional tertiary hospitals.

“India’s growing cancer burden requires us to rethink how cancer care is delivered. Innovations such as subcutaneous immunotherapy have the potential to simplify treatment administration, reduce pressure on hospital beds and support more decentralised models of care beyond large metro hospitals,” said Dr Amit Rauthan, Consultant and HOD of Medical Oncology at Manipal Hospital.

Read More: India Better Prepared For Hantavirus Outbreaks After COVID-19 Experience, Says Dr NK Ganguly | Exclusive

Tecentriq SC: Safety

Global studies have indicated strong patient preference for subcutaneous administration.

According to results from the IMscin002 study presented at the European Lung Cancer Congress (ELCC) 2024:

• Four out of five patients preferred Tecentriq SC over IV administration
• Patients cited less time in clinics, greater comfort, and lower emotional distress as key reasons for preference

Studies have also shown that subcutaneous administration is associated with less discomfort, pain, and irritation compared to IV administration.

In the IMscin001 study presented at ESMO 2023:

• 90 per cent of healthcare professionals agreed the SC formulation was easy to administer
• 75 per cent believed it could save time for healthcare teams.

Even as Polycystic Ovary Syndrome (PCOS) got rebranded as Polyendocrine Metabolic Ovarian Syndrome (PMOS), it signals a major shift in how doctors understand and treat one of the most common hormonal conditions affecting women, said health experts today.

Speaking to HealthandMe, the experts noted that from the earlier narrowed focus on ovarian cysts, the transition toward PMOS will better capture the condition’s complex metabolic and endocrine nature.

Dr. Isha Kriplani, Consultant – Obstetrics and Gynecology at Paras Health, said the renaming marks “the beginning of a new era in women's gynecological health.”

What Does PMOS Mean?

Also read: PCOS Is Now PMOS: What The Name Change Means For Millions Of Women

The new name aims to explain the condition more accurately and comprehensively.

Polyendocrine means it affects multiple hormones in the body.

Metabolic refers to issues linked to weight, insulin, blood sugar, and heart health.

Ovarian highlights its impact on ovulation and reproductive health.

Syndrome refers to a group of symptoms occurring together.

In simple terms, PMOS is a hormonal and metabolic condition that can affect periods, fertility, skin, mood, weight, and long-term health.

How Will The Change Impact Women

Dr. Isha stated that the term PMOS acknowledges that the disorder is not solely linked to hormonal imbalance or ovarian dysfunction, but also deeply connected to metabolic health. She explained that many women experience symptoms such as weight gain, skin issues, fatigue, insulin resistance, and hormonal disturbances without necessarily showing ovarian cysts on ultrasonography.

“Rebranding Polycystic Ovary Syndrome (PCOS) into Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the beginning of a new era in women's gynecological health. This is because renaming helps us understand that the complex interplay of this disease is not only about imbalanced hormones but also metabolism,” she told HealthandMe.

Dr. Isha added that the shift could help broaden diagnosis and encourage early intervention to prevent long-term complications such as type 2 diabetes and hypertension. She noted that the new terminology also provides women with a more accurate understanding of the syndrome and encourages treatment strategies focused on addressing the root metabolic causes.

Why The Change To PMOS Was Necessary

Dr. Raina Chawla, Associate Director – Gynecology at Sarvodaya Hospital, told HealthandMe the transition from PCOS to PMOS corrects what she described as one of medicine’s “most persistent misnomers.”

She explained that for years, the term PCOS led many patients to believe the condition was purely ovarian in nature, often resulting in confusion and delays in diagnosis. According to Dr. Raina, the so-called “cysts” seen in PCOS are actually immature follicles that develop as a consequence of the disorder rather than being its primary cause.

Also read: PCOD vs PCOS vs PMOS: Why The Condition’s Name Has Changed Over Time

“The shift from PCOS to Reproductive Metabolic Syndrome (PMOS) is an important move toward correcting one of medicine’s most persistent misnomers,” Dr. Raina said.

She further emphasized that the newer terminology places appropriate attention on insulin resistance and androgen excess, helping doctors and patients approach the disorder as a systemic endocrine and metabolic condition rather than a localized ovarian issue.

Experts believe the change in terminology could also reduce stigma and improve awareness about the wide-ranging symptoms associated with the syndrome, while encouraging a more holistic treatment approach that includes lifestyle modifications, metabolic screening, and long-term preventive care.